Latest news with #ApotexInc
Cision Canada
27-05-2025
- Business
- Cision Canada
Apotex launches nilotinib capsules, the first generic version of Tasigna®(1) in the United States, with 180 days of exclusivity
WESTON, Fla., May 27, 2025 /CNW/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the United States, with 180 days of exclusivity. Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments. "The launch of nilotinib highlights our commitment to providing affordable, high-quality, critical medications to patients in need," said Christine Baeder, President, Apotex USA. "By offering the first generic version of this important leukemia treatment, we improve access and outcomes for both adult and pediatric patients facing this serious disease." Please refer to the complete prescribing information, patient information leaflet, warnings and precautions, adverse reactions, and contraindications. About Apotex Apotex Corp., headquartered in Weston, Florida, is an affiliate of Apotex Inc. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at SOURCE Apotex Inc.
Yahoo
27-05-2025
- Business
- Yahoo
Apotex launches nilotinib capsules, the first generic version of Tasigna®(1) in the United States, with 180 days of exclusivity
WESTON, Fla., May 27, 2025 /CNW/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the United States, with 180 days of exclusivity. Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments. "The launch of nilotinib highlights our commitment to providing affordable, high-quality, critical medications to patients in need," said Christine Baeder, President, Apotex USA. "By offering the first generic version of this important leukemia treatment, we improve access and outcomes for both adult and pediatric patients facing this serious disease." Please refer to the complete prescribing information, patient information leaflet, warnings and precautions, adverse reactions, and contraindications. About Apotex Apotex Corp., headquartered in Weston, Florida, is an affiliate of Apotex Inc. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at _______________________________1 Tasigna® is a registered trademark of Novartis AG View original content to download multimedia: SOURCE Apotex Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
20-05-2025
- Business
- Cision Canada
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
TORONTO, May 20, 2025 /CNW/ - Apotex Inc. ("Apotex"), the Canadian-based global health company, today published its 2024 Sustainability Report, showcasing its ongoing commitment to sustainable, responsible business practices and its global impact. Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex. Key achievements include: Sourcing 81% of global electricity consumption from renewable or low-carbon sources in 2024 and significant reductions in Scope 1 and 2 emissions through the implementation of energy-efficient technologies across our facilities More than $1.5 million in essential products donated to vulnerable populations in 2024, and the establishment of the Apotex Global Health Access Fund, which provides long-term funding to support maternal health initiatives in Canada, the United States, Mexico, and India Enhancement of Apotex's Global Risk Management Program and strengthening the Global Business Ethics and Compliance Program to further enhance transparency and accountability Hiring a new Head of Sustainability to further advance Apotex's enterprise-wise ESG strategy Apotex has also made strides in waste management, achieving notable reductions in waste generation by applying green chemistry principles and innovative recycling programs, and aims to continue implementing energy-efficient technologies and renewable energy solutions to further reduce its environmental footprint. Learn more about sustainability at Apotex. About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people worldwide, with a broad portfolio of generic, biosimilar, innovative branded pharmaceuticals and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at
Yahoo
20-05-2025
- Business
- Yahoo
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
TORONTO, May 20, 2025 /PRNewswire/ - Apotex Inc. ("Apotex"), the Canadian-based global health company, today published its 2024 Sustainability Report, showcasing its ongoing commitment to sustainable, responsible business practices and its global impact. Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex. Key achievements include: Sourcing 81% of global electricity consumption from renewable or low-carbon sources in 2024 and significant reductions in Scope 1 and 2 emissions through the implementation of energy-efficient technologies across our facilities More than $1.5 million in essential products donated to vulnerable populations in 2024, and the establishment of the Apotex Global Health Access Fund, which provides long-term funding to support maternal health initiatives in Canada, the United States, Mexico, and India Enhancement of Apotex's Global Risk Management Program and strengthening the Global Business Ethics and Compliance Program to further enhance transparency and accountability Hiring a new Head of Sustainability to further advance Apotex's enterprise-wise ESG strategy Apotex has also made strides in waste management, achieving notable reductions in waste generation by applying green chemistry principles and innovative recycling programs, and aims to continue implementing energy-efficient technologies and renewable energy solutions to further reduce its environmental footprint. Learn more about sustainability at Apotex. About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people worldwide, with a broad portfolio of generic, biosimilar, innovative branded pharmaceuticals and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at View original content to download multimedia: SOURCE Apotex Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
09-05-2025
- Business
- Cision Canada
Apotex introduces IVRA™ (Melphalan) hydrochloride injection: First ready to dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States
WESTON, Fla., May 9, 2025 /CNW/ - Apotex Corp. today launched IVRA™ (Melphalan) hydrochloride injection 90mg/ml multidose vial ("IVRA"), first ready-to-dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States. IVRA is an alkylating drug indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate, and will be distributed primarily through hospital and institutional channels. "The launch of IVRA highlights Apotex's uncompromising dedication to access, innovation, and patient care," said Christine Baeder, President, Apotex USA. "As we introduce our novel ready-to-dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States, we reinforce our commitment to bringing much-needed products that support patients on their health journeys." Please refer to the complete prescribing information, patient information leaflet, warnings and precautions, adverse reactions, and contraindications. About Apotex Apotex Corp., headquartered in Weston, Florida, is an affiliate of Apotex Inc. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at SOURCE Apotex Inc.
